In a regulatory 13G filing, Pfizer (PFE) disclosed that it has taken a 12% or 5.38M share stake in Oric Pharmaceuticals (ORIC). Shares of Oric are up 3% afterhours at $5.44. On December 21st, Oric Pharmaceuticals also initially announced that its plans to partner with Pfizer on ORIC-533 and receive a $25M investment from the company.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ORIC:
- Oric Pharmaceuticals (NASDAQ:ORIC) Stock Spikes on Pfizer Deal
- Oric Pharmaceuticals to partner with Pfizer on ORIC-533, gets $25M investment
- ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer
- Oric Pharmaceuticals presents preclinical data on ORIC-533
- ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting